Is larotrectinib available in China? Is it easy to buy

Introduction: Larotrectinib (Vitrakvi) has been successfully launched in China, bringing new treatment hope to many patients with NTRK gene fusion tumors. Its unique targeting mechanism and significant therapeutic effect made larotrectinib quickly become the focus of attention from the medical community and patients after its launch. This article will introduce in detail the marketing information of larotrectinib in China and discuss its treatment methods for hypoalbuminemia.

Larotinib’s marketing information in China

On April 13, 2022, larotrectinib (trade name: Vitrakvi®) was officially approved by the China National Medical Products Administration, becoming China’s first broad-spectrum targeted drug that does not differentiate between tumor sources. This landmark approval marks a major advancement in the field of cancer treatment in China and provides new treatment options for patients with advanced or metastatic solid tumors, especially those with NTRK gene fusions. The launch of not only enriches the domestic drug library for tumor treatment, but also further promotes the development of precision medicine in China.

The launch of larotrectinib is based on its extensive research and clinical trial data worldwide. As the first oral TRK inhibitor drug officially approved for marketing, larotrectinib has shown remarkable efficacy in the treatment of various types of NTRK gene fusion tumors. Its unique targeting mechanism allows the drug to accurately act on tumor cells, thereby inhibiting the growth and spread of tumors. In China, the launch of larotrectinib has also gone through a strict approval process.

Treatment of larotrectinib and hypoalbuminemia

Although larotrectinib performs well in the treatment of NTRK gene fusion tumors, patients may still experience some adverse reactions during use, of which hypoalbuminemia is a common one. Hypoalbuminemia refers to a pathological state in which the albumin concentration in the blood is lower than the normal range. It may be caused by a variety of reasons, including malnutrition, impaired liver function, abnormal renal function, and side effects of certain drugs.

For hypoalbuminemia caused by larotrectinib, the following treatments can be taken:

Nutritional support: Patients should ensure that they receive adequate nutritional support, especially protein-rich foods. This helps increase the concentration of albumin in the blood and improves symptoms of hypoalbuminemia.

Drug treatment: For patients with more severe symptoms, drug treatment can be considered. For example, intravenous injection of human albumin can quickly increase the concentration of albumin in the blood, but this treatment should be carried out under the guidance of a doctor to avoid the risk of overdose.

Adjust treatment plan: If hypoalbuminemia is caused by larotrectinib and symptoms persist and are severe, your doctor may consider adjusting the treatment plan. This may include reducing the dose of the medication, suspending the medication, or switching to another treatment. When adjusting the treatment plan, the patient's specific situation and disease progression should be taken into consideration.

Monitoring and follow-up: During treatment, patients should be closely monitored for albumin levels and related symptoms. Through regular blood tests and clinical assessment, adverse reactions such as hypoalbuminemia can be detected and dealt with promptly to ensure the safety of patient treatment.